MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX�� Orally Inhaled Migraine Drug

reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug...